- Home
- BEAT vs BYSI Comparison
BEAT vs BYSI Comparison
Compare BEAT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- BYSI
- Stock Information
- Founded
- BEAT 2015
- BYSI 2010
- Country
- BEAT United States
- BYSI United States
- Employees
- BEAT N/A
- BYSI N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- BYSI Health Care
- Exchange
- BEAT Nasdaq
- BYSI Nasdaq
- Market Cap
- BEAT 74.1M
- BYSI 69.3M
- IPO Year
- BEAT 2021
- BYSI 2017
- Fundamental
- Price
- BEAT $2.14
- BYSI $1.72
- Analyst Decision
- BEAT Buy
- BYSI
- Analyst Count
- BEAT 1
- BYSI 0
- Target Price
- BEAT $8.00
- BYSI N/A
- AVG Volume (30 Days)
- BEAT 117.1K
- BYSI 21.8K
- Earning Date
- BEAT 11-07-2024
- BYSI 01-01-0001
- Dividend Yield
- BEAT N/A
- BYSI N/A
- EPS Growth
- BEAT N/A
- BYSI N/A
- EPS
- BEAT N/A
- BYSI N/A
- Revenue
- BEAT N/A
- BYSI $1,876,000.00
- Revenue This Year
- BEAT N/A
- BYSI N/A
- Revenue Next Year
- BEAT N/A
- BYSI N/A
- P/E Ratio
- BEAT N/A
- BYSI N/A
- Revenue Growth
- BEAT N/A
- BYSI 21.03
- 52 Week Low
- BEAT $1.35
- BYSI $0.82
- 52 Week High
- BEAT $3.48
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- BEAT 39.59
- BYSI 52.47
- Support Level
- BEAT $2.00
- BYSI $1.58
- Resistance Level
- BEAT $2.30
- BYSI $1.75
- Average True Range (ATR)
- BEAT 0.16
- BYSI 0.09
- MACD
- BEAT -0.00
- BYSI 0.02
- Stochastic Oscillator
- BEAT 35.00
- BYSI 74.07
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.